Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $152 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $152.
May 29, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $152.
The reiteration of an Outperform rating and a maintained price target of $152 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100